Cullinan Therapeutics (CGEM) Interest Coverage Ratio: History & Chart

Cullinan Therapeutics, Inc.(CGEM)

Biotechnology · Cambridge, MA

$16.46+0.42 (+2.64%)

Delayed quote: Oct 6, 2026, 2:45 PM EDT

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cambridge, MA

109 employees

cullinantherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Nadim Ahmed

View full financials

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Cullinan Therapeutics, Inc. (CGEM)	$1.01B	N/A	N/A	N/A	N/A
Immatics N.V. (IMTX)vs ›	$1.02B	-192.41x	28.86x	28.86x	28.86x
Castle Biosciences, Inc. (CSTL)vs ›	$1.02B	-497.79x	15.03x	15.03x	8.31x
Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs ›	$1.02B	0.23x	0.32x	0.27x	0.27x
Janux Therapeutics, Inc. (JANX)vs ›	$1.03B	N/A	N/A	N/A	N/A
Vor Biopharma Inc. (VOR)vs ›	$996.36M	N/A	N/A	N/A	N/A
Integra LifeSciences Holdings Corporation (IART)vs ›	$1.03B	0.79x	0.59x	2.04x	2.37x
Latigo Biotherapeutics Inc. (LTGO)vs ›	$988.36M	N/A	N/A	N/A	N/A
MeiraGTx Holdings plc (MGTX)vs ›	$989.07M	-8.69x	N/A	N/A	N/A
PROCEPT BioRobotics Corporation (PRCT)vs ›	$986.26M	-28.96x	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Cullinan Therapeutics, Inc. (CGEM)

$1.01B

N/A

Immatics N.V. (IMTX)vs ›

$1.02B

-192.41x

28.86x

Castle Biosciences, Inc. (CSTL)vs ›